Kim SU, et al. - In treatment-naïve patients with CHB, researchers evaluated the ability of entecavir (ETV) vs tenofovir disoproxil fumarate (TDF) to prevent progression of liver disease. Treatment-naïve CHB patients were recruited from four academic teaching hospitals from 2012 to 2014 to receive ETV or TDF as a first–line antiviral agent. Patients were excluded from enrollment if they had decompensated cirrhosis or hepatocellular carcinoma (HCC). Cumulative HCC and death or orthotopic liver transplant (OLT) probabilities were evaluated. They recruited 2,897 patients. Between the ETV and TDF groups, the overall HCC and death or OLT prognosis were not statistically different between. In patients with compensated cirrhosis, these findings were consistently reproduced.